Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Support

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Press 2007

Cleveland Clinic & Medical Device Innovations, LLC, Form Clear Catheter Solutions LLC

by James Herlofsky

Oregon incubator, Clinic form joint ventures

by James Herlofsky

Recent Press

Randomized Clinical Trial Results Confirm PleuraFlow Reduces Take Back for Bleeding in Cardiac Surgery Patients
PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results
New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients
ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations
ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan

Archives

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2007

Press Contact:

Paul Williams
MediaLine Communications
(949) 916-6880
paul@medialinecommunications.com

or

James Herlofsky, Marketing Manager
ClearFlow, Inc.
(310) 569-5604
jherlofsky@clearflow.com

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Clinical References| Terms of Use| PleuraFlow ACT System Indications of Use|

PleuraFlow® ACT® is not indicated as a therapeutic device.

ClearFlow’s PleuraFlow® Active Clearance Technology® and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759, 8,702,662 and 8,951,355. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow’s patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.

Website by Bloom Creative